Health‐related quality of life and well‐being in pediatric patients with alopecia areata and their caregivers

Alopecia areata (AA) is a nonscarring autoimmune hair loss that affects all age groups. Children and adolescents with AA often experience changes in body image due to hair loss, which can be especially pronounced during the vulnerable period of puberty. This commonly affects self-confidence, social relationships, and school performance.1 A higher rate of limitations in leisure activities and increased instances of bullying may also be present. Pediatric AA may also have a detrimental impact on patients' caregivers, affecting them both psychosocially and economically. Psychosocial impacts include worrying about the child and feelings of exclusion from certain social activities, while the economic burden stems from time spent accompanying the child to medical appointments and the costs of treatments. While the impact of AA on adults has been relatively well studied using various standardized health-related quality of life (HRQoL) measures,2 little is known about the HRQoL in pediatric patients with AA. A recent systematic literature review identified only eight studies with a cumulative sample size of fewer than 400 patients.3 In this issue of the Journal, the study by Yücesoy et al.4 makes a valuable contribution to the literature. The authors conducted a cross-sectional survey of 72 pediatric AA patients aged 7–16 years and their parent caregivers in Türkiye. The patients' HRQoL was measured through the widely used Children's Dermatology Life Quality Index (CDLQI), while the caregivers' HRQoL and well-being were assessed using a locally developed scale, the Dermatological Family Impact Scale (DeFIS). Patients experienced the most difficulties with treatment (87%), followed by feelings of embarrassment, self-consciousness, upset or sadness (75%), and issues related to itchy, “scratchy,” sore or painful skin (68%). The mean CDLQI score in the sample was 8.4, indicating a similar impact on patients' lives as other chronic skin conditions, including pediatric atopic dermatitis (8.5), psoriasis (8.0), and urticaria (7.1), according to a large meta-analysis.5 More severe AA, as measured by the Severity of Alopecia Tool, and nail involvement were associated with lower HRQoL. Over 90% of caregivers reported feelings of sadness and anxiety due to their child's condition. Girls and boys, as well as mothers and fathers, showed equally impaired HRQoL and well-being, as reflected in the overall CDLQI and DeFIS scores. However, the parents of female patients experienced significantly more HRQoL and well-being problems. Measuring the HRQoL and well-being of both patients and caregivers is essential for clinicians to understand the patient and family perspective better, inform treatment decisions, and highlight the burden of the disease to policymakers and society, which may underestimate the impact of AA. Additionally, assessing HRQoL is pivotal for conducting cost-effectiveness analyses that inform resource allocation decisions for new treatments and social policies to support affected families. This is particularly relevant now, as new treatments, such as ritlecitinib, have recently been approved by both the U.S. Food and Drug Administration and the European Medicines Agency for treating severe AA in patients aged 12 years and older. Studies like Yücesoy et al.4 are valuable for illustrating the burden of illness. However, the HRQoL instruments used in this study were not specifically validated for this population, and there is limited evidence regarding their psychometric performance in the context of pediatric AA populations. Moreover, the CDLQI is not a preference-based measure of HRQoL, unlike the EQ-5D-Y or Child Health Utility 9D, which allow for the estimation of utilities and quality-adjusted life years for cost-effectiveness analyses. Therefore, further efforts are needed to validate HRQoL measures and assess health utilities in this population.